Skip Navigation LinksHome > January 27, 2012 - Volume 93 - Issue 2 > Cost-Effectiveness of Cidofovir Treatment of Polyomavirus Ne...
Transplantation:
doi: 10.1097/TP.0b013e31823e7b0e
Clinical and Translational Research

Cost-Effectiveness of Cidofovir Treatment of Polyomavirus Nephropathy in Kidney Transplant Recipients

Hua, Danny K.1; Howard, Kirsten2; Craig, Jonathan C.1,2; Chapman, Jeremy R.3; Wong, Germaine1,2,3,4

Supplemental Author Material
Collapse Box

Abstract

Background. BK virus nephropathy (BKVAN) causes about 10% of late kidney graft loss. Cidofovir is widely used to treat BKVAN, but the magnitude of the health benefits and costs are largely unknown. We aimed to evaluate the incremental health benefits and costs of cidofovir and immunosuppression reduction compared with immunosuppression reduction alone in kidney transplant patients with BKVAN.

Methods. A probabilistic decision analytic model was developed to simulate a cohort of kidney transplant recipients aged 45 years and above with BKVAN who received cidofovir treatment compared with those who received standard care. The duration of the cycle was 1 year, and the model terminated when all recipients were deceased.

Results. Compared with immunosuppression reduction alone, in the base-case, the incremental health benefits of cidofovir were 0.0061 life-years saved (2.2 days), with savings of $20,756 over the lifetime of a transplant recipient. When varying the most influential variables (the probability of response to treatment and graft loss) between best and worst case scenarios, the incremental health outcomes ranged from −0.967 to 1.093 life-years saved, with incremental costs ranging from an extra $27,313 to saving $20,756.

Conclusions. Compared with immunosuppression reduction alone, based on best available data, cidofovir treatment and immunosuppression reduction for BKVAN seem to be cost saving and improves health outcomes. However, because of weak clinical data, particularly around comparative effectiveness, there is still moderate uncertainty in the incremental cost effectiveness. Adequately powered trials are still needed to better define optimal treatment strategies for BKVAN before cidofovir can be recommended strongly as routine therapy.

© 2012 Lippincott Williams & Wilkins, Inc.

 

 

 

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.